Novartis announced on August 25 that the China Drug Administration has approved a combination of radioligand therapy drug Pavital® and an androgen receptor pathway inhibitor to treat prostate-specific membrane antigen-positive metastatic hormone-sensitive prostate cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.